News

The past year has provided great steps forward in sleep science, and coupled with the lingering difficulties in care and the COVID-19 pandemic’s effects, the field is coming to a head to make sleep health a public health priority.

Neither finasteride nor dutasteride were linked to an increased risk of suicide.

The FDA's plans to expedite and expand regulatory pathways has resulted in a novel drug development boom since 2017. The commissioner discusses the details of their strategy.

In the December 2022 episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down to discuss recent developments in the field, with a spotlight on the Dexcom G7 CGM, key takeaways from the ADA’s Standards of Care in Diabetes—2023, and perspective from the ADCES Diabetes Technology Conference 2022.

A new study explored the topic of predictive biomarkers of clinical improvement of EASI scores for atopic dermatitis patients being given dupilumab.

Dr. Adam Lamble recommends that pediatric patients with AML and TP53 status should now be considered for transplant in first remission, and novel interventions are warranted.

In part A of the trial, 60% of patients treated with dupilumab weekly met the primary endpoint of histologic remission, compared to 5% of the placebo group.

There was a decrease in relapse observed for low-risk participants, but not high-risk individuals.

As physician demands continue to climb in the high-demand specialty, patient-reported outcomes have emerged as a viable tool in assessment and care.

A new Q&A focuses on hybrid telehealth in ophthalmology and subspecialty-level care, and its potential to create new opportunities and increase access for patients.

In this episode of Diabetes Dialogue, Jill Weissberg-Benchell, PhD, takes hosts through her journey to becoming a diabetes care and education specialist, the role of psychologists in the management of pediatric diabetes, and her thoughts on the evolving role of care and education specialists in the management of diabetes.

With the population aging, there is a need for new treatments in nephrology.

Almost 25 years later, Dr. Claudia Morris concluded 2022 by presenting phase 2 data at the 64th ASH Annual Meeting that demonstrated the therapy's benefit, and her original premise. Her team's phase 3 trial evaluating Arg is currently underway.

There was no differences observed in total weight loss at both 6 and 18 months in the fecal microbiota transplantation and placebo groups.

Meta-analysis data show female, Black and Asian participants are generally underrepresented across studies assessing COVID-19 prevention or treatment strategies.

The indication makes tocilizumab the first monoclonal antibody to be granted full FDA approval to treat the pandemic virus.

Lawrence Eichenfield, MD, reviews major drug approvals and advancement of screening and prevention strategies for the youngest patients with atopic dermatitis.

Dr. Adam Lamble shares that outcomes for pediatric patients with acute myeloid leukemia that have TP53 status are inferior to other patients with high-risk disease.

Dr. Corinna Schultz talks about her latest data and the growing body of literature showing medical complications that can come with sickle cell trait.

A continued discussion with Dr. Bays on anti-obesity therapies down the line and where they might be in the near future.

Anti-obesity medications have the potential for significant weight reduction, but the development of newer agents may lead to an even greater change in obesity care.

In this episode of Diabetes Dialogue, Richard Bergenstal, MD, sits down with hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss the role and evolution of technology in the management of diabetes.

"Using CRISPR/Cas9 you are able to actually fix a disease, that otherwise, was not fixable," Dr. Haydar Frangoul explains the data he presented at ASH 2022.

As 2022 concludes, a dermatologist reflects on the first drug approved for vitiligo.

A moderate negative correlation was observed between changes in BCVA and changes in CST at weeks 12 and 24.

Some in the industry expect the Adderall shortage to possibly last until March 2023.

An analysis of NHANES data spanning more than 3 decades provides an overview of trends in glycemic control and severe hyperglycemia among people with diabetes using insulin, including racial and ethnic disparities.

Dupilumab use surpassed all conventional systemic drug use since its introduction in 2017 until the end of the study in 2020-21.